These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3987792)

  • 1. Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment.
    Schlicht F; Staiger C; de Vries J; Gundert-Remy U; Hildebrandt R; Harenberg J; Wang NS; Weber E
    Eur J Clin Pharmacol; 1985; 28(1):97-103. PubMed ID: 3987792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine.
    Bradbrook ID; John VA; Morrison PJ; Rogers HJ; Spector RG
    Br J Clin Pharmacol; 1982 Feb; 13(2):177-85. PubMed ID: 7059415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state.
    Rosenkranz B; Fischer C; Jakobsen P; Kirstein Pedersen A; Frölich JC
    Eur J Clin Pharmacol; 1983; 24(2):231-5. PubMed ID: 6840173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulphinpyrazone metabolism during long-term therapy.
    Pedersen AK; Jakobsen P
    Br J Clin Pharmacol; 1981 Jun; 11(6):597-603. PubMed ID: 7272176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal clearance of sulphinpyrazone in man.
    Lentjes EG; Russel FG; van Ginneken CA
    Eur J Clin Pharmacol; 1986; 31(4):473-8. PubMed ID: 3816927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New metabolites of sulfinpyrazone in man.
    Dieterle W; Faigle JW; Moppert J
    Arzneimittelforschung; 1980; 30(6):989-93. PubMed ID: 7191279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The site of reduction of sulphinpyrazone in the rabbit.
    Strong HA; Renwick AG; George CF
    Xenobiotica; 1984 Oct; 14(10):815-26. PubMed ID: 6506754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination.
    Miners JO; Foenander T; Wanwimolruk S; Gallus AS; Birkett DJ
    Eur J Clin Pharmacol; 1982; 22(4):321-6. PubMed ID: 7106168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the gut flora in the reduction of sulphinpyrazone in the rat.
    Renwick AG; Evans SP; Sweatman TW; Cumberland J; George CF
    Biochem Pharmacol; 1982 Aug; 31(16):2649-56. PubMed ID: 7138558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics and metabolism of sulfinpyrazone.
    Mahony C; Wolfram KM; Nash PV; Bjornsson TD
    Clin Pharmacol Ther; 1983 Apr; 33(4):491-7. PubMed ID: 6831828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol.
    Staiger C; Schlicht F; Walter E; Gundert-Remy U; Hildebrandt R; de Vries J; Wang NS; Harenberg J; Weber E
    Eur J Clin Pharmacol; 1983; 25(6):797-801. PubMed ID: 6141054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-performance liquid chromatographic determination of sulfinpyrazone and its metabolites in plasma.
    Kuo BS; Kaplan LA; Ritschel WA
    Arzneimittelforschung; 1984; 34(5):548-50. PubMed ID: 6540568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man.
    Dieterle W; Faigle JW; Mory H; Richter WJ; Theobald W
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):135-45. PubMed ID: 786687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of sulphinpyrazone and its metabolites on platelet function in vitro and ex vivo.
    Pay GF; Wallis RB; Zelaschi D
    Haemostasis; 1981; 10(3):165-75. PubMed ID: 7262645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ischaemic heart disease, Crohn's disease and antimicrobial therapy on the pharmacokinetics of sulphinpyrazone.
    Strong HA; Angus R; Oates J; Sembi J; Howarth P; Renwick AG; George CF
    Clin Pharmacokinet; 1986; 11(5):402-10. PubMed ID: 3780113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites.
    He M; Kunze KL; Trager WF
    Drug Metab Dispos; 1995 Jun; 23(6):659-63. PubMed ID: 7587949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the gut flora in the reduction of sulfinpyrazone in humans.
    Strong HA; Oates J; Sembi J; Renwick AG; George CF
    J Pharmacol Exp Ther; 1984 Sep; 230(3):726-32. PubMed ID: 6470977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verapamil disposition--effects of sulphinpyrazone and cimetidine.
    Wing LM; Miners JO; Lillywhite KJ
    Br J Clin Pharmacol; 1985 Mar; 19(3):385-91. PubMed ID: 3986090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reduction of sulphinpyrazone and sulindac by intestinal bacteria.
    Strong HA; Renwick AG; George CF; Liu YF; Hill MJ
    Xenobiotica; 1987 Jun; 17(6):685-96. PubMed ID: 3630204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of sulphinpyrazone with warfarin.
    Miners JO; Foenander T; Wanwimolruk S; Gallus AS; Birkett DJ
    Eur J Clin Pharmacol; 1982; 22(4):327-31. PubMed ID: 7106169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.